Jiaqin Yan

1.2k total citations
39 papers, 534 citations indexed

About

Jiaqin Yan is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Jiaqin Yan has authored 39 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 10 papers in Immunology. Recurrent topics in Jiaqin Yan's work include Lymphoma Diagnosis and Treatment (23 papers), CAR-T cell therapy research (7 papers) and Immune Cell Function and Interaction (6 papers). Jiaqin Yan is often cited by papers focused on Lymphoma Diagnosis and Treatment (23 papers), CAR-T cell therapy research (7 papers) and Immune Cell Function and Interaction (6 papers). Jiaqin Yan collaborates with scholars based in China and United States. Jiaqin Yan's co-authors include Zhaoming Li, Yu Chang, Xiaorui Fu, Ling Li, Jingjing Wu, Feifei Nan, Zhenchang Sun, Xinhua Wang, Lei Zhang and Mingzhi Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemical and Biophysical Research Communications.

In The Last Decade

Jiaqin Yan

38 papers receiving 530 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiaqin Yan China 13 338 310 197 118 60 39 534
Chengfeng Bi China 12 325 1.0× 256 0.8× 97 0.5× 162 1.4× 88 1.5× 29 536
Alina Danu France 10 169 0.5× 246 0.8× 104 0.5× 47 0.4× 34 0.6× 38 377
Akito Dobashi Japan 9 205 0.6× 188 0.6× 69 0.4× 83 0.7× 47 0.8× 18 384
Hong Yi Wang United States 7 205 0.6× 531 1.7× 383 1.9× 175 1.5× 50 0.8× 12 791
Rajai Al-Jehani United Kingdom 9 243 0.7× 191 0.6× 132 0.7× 82 0.7× 43 0.7× 11 409
Kana Miyazaki Japan 12 285 0.8× 228 0.7× 86 0.4× 50 0.4× 95 1.6× 46 403
Gabriel Prolla Brazil 8 158 0.5× 196 0.6× 118 0.6× 97 0.8× 41 0.7× 17 427
Willi Woessmann Germany 14 439 1.3× 215 0.7× 100 0.5× 156 1.3× 58 1.0× 20 656
Justus Duyster Germany 8 173 0.5× 145 0.5× 140 0.7× 144 1.2× 72 1.2× 11 490

Countries citing papers authored by Jiaqin Yan

Since Specialization
Citations

This map shows the geographic impact of Jiaqin Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiaqin Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiaqin Yan more than expected).

Fields of papers citing papers by Jiaqin Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiaqin Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiaqin Yan. The network helps show where Jiaqin Yan may publish in the future.

Co-authorship network of co-authors of Jiaqin Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Jiaqin Yan. A scholar is included among the top collaborators of Jiaqin Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiaqin Yan. Jiaqin Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Zhao, Jiaqin Yan, Fang Ren, et al.. (2025). Single-cell transcriptomic analyses reveal heterogeneity and key subsets associated with survival and response to PD-1 blockade in cervical squamous cell carcinoma. Cancer Cell International. 25(1). 90–90. 1 indexed citations
2.
Wen, Xin, Hui Yu, Lei Zhang, et al.. (2024). The relationship and clinical significance of serum cytokine expression level and skin pruritus in patients with Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma. International Immunopharmacology. 131. 111777–111777. 1 indexed citations
3.
Zhang, Xudong, Xiaoyan Feng, Meng Dong, et al.. (2023). Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma. Cancer Medicine. 12(7). 8134–8143. 7 indexed citations
4.
Wang, Huanrong, Lei Liu, Jiaqin Yan, et al.. (2023). Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse. Frontiers in Oncology. 12. 1097816–1097816. 4 indexed citations
5.
He, Jian, et al.. (2023). NALCN is a potential biomarker and therapeutic target in human cancers. Frontiers in Genetics. 14. 1164707–1164707. 5 indexed citations
6.
Yu, Hui, Xiaorui Fu, Lei Zhang, et al.. (2021). Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system. Hematological Oncology. 41(2). 267–274. 2 indexed citations
7.
Li, Ling, Lei Zhang, Xin Li, et al.. (2021). Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion. 38(1). 42–50. 2 indexed citations
8.
9.
Zhang, Lei, Ling Li, Xin Li, et al.. (2020). <p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p>. OncoTargets and Therapy. Volume 13. 7189–7197. 11 indexed citations
10.
Zhang, Lei, Xin Li, Ling Li, et al.. (2020). Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. European Journal of Radiology. 133. 109301–109301. 10 indexed citations
11.
Yan, Jiaqin, Junhui Zhang, Xudong Zhang, et al.. (2018). AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. Molecular Medicine. 24(1). 35–35. 18 indexed citations
12.
Zhang, Xudong, Xiaorui Fu, Meng Dong, et al.. (2018). Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. Cancer Cell International. 18(1). 150–150. 5 indexed citations
13.
Wu, Jingjing, Lingling Duan, Lei Zhang, et al.. (2018). Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. Journal of Neuro-Oncology. 140(2). 427–434. 19 indexed citations
14.
15.
Li, Ling, Ken H. Young, Lei Zhang, et al.. (2017). Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study. Blood. 130. 1548–1548. 2 indexed citations
16.
Li, Ling, Wenjing Duan, Lei Zhang, et al.. (2017). The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T‐cell lymphoma with analysis of biomarkers. British Journal of Haematology. 178(5). 772–780. 21 indexed citations
17.
Cui, Yingying, Xin Li, Zhenchang Sun, et al.. (2015). Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leukemia & lymphoma. 56(9). 2613–2618. 11 indexed citations
18.
Cui, Yingying, Zhenchang Sun, Xin Li, et al.. (2015). Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. Oncology Letters. 11(1). 693–698. 15 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chengfeng Bi Breakdown of academic impact, for papers by Alina Danu Breakdown of academic impact, for papers by Akito Dobashi Breakdown of academic impact, for papers by Hong Yi Wang Breakdown of academic impact, for papers by Rajai Al-Jehani Breakdown of academic impact, for papers by Kana Miyazaki Breakdown of academic impact, for papers by Gabriel Prolla Breakdown of academic impact, for papers by Willi Woessmann Breakdown of academic impact, for papers by Justus Duyster
Rankless by CCL
2026